ARTICLE | Management Tracks
Former bluebird CEO picked to lead Inventiva
Plus: Cross-border dealmaker Jun Bao leaving Biotheus for early-stage VC, Edwards joining Forbion, and updates from Immatics, Climb Bio, AiRNA and Cue
October 1, 2025 10:24 PM UTC
With its therapy for metabolic dysfunction-associated steatohepatitis in Phase III testing, France-based Inventiva S.A. (Euronext:IVA; NASDAQ:IVA) has tapped former bluebird bio Inc. CEO Andrew Obenshain as its new CEO. He will replace co-founder Frédéric Cren, who is also stepping down as a director. Obenshain will take a seat on the board.
Inventiva said the decision reflects the company’s preparation to commercialize PPARα, PPARγ and PPARδ agonist lanifibranor in the U.S. while broadening the company’s global footprint...